Hi All,
WOW what a day for ACW on positive news of cognitive improvement in healthy OLDER adults @ 20mg Xanamem from first cohort in Xanahes Trial (Ph1) & nil safety concerns reported.
I see there is a recording of a conference call today on Actinogen website, so going to listen to that now.
This is big news for us, after a Ph2 trial failure in AD at 10mg dose of Xanamem. Looking forward to what Dr Bill has to say & some of my fellow investors questions also.
I’ve had a quick read through posts from today & I agree with those who thought this may bring some International attention in Biotech/Pharma focused online media in such a huge clinically unmet need with multiple large trial failures recently that had a lot of hope (and Big Pharma money riding on them) recently. It’s been back to Ph1 for us, so early days, but we are talking potentially a treatment for early AD here, & also potentially cognitive decline in the older person; also other indications that go hand in hand with that; depression & other MH disorders, but depression is the BIG one.
GLTAH who held on & it’s great to be very green again, but I understand some may not be even on a 400% + SP hike. I initially bought this stock unloved on FA & then again after Xanadu 10mg results. It appears the market is paying attention to important results here now. Best wishes all.
